Leptin treatment of multiple symmetric lipomatosis due to a mitochondrial defect
Ugeskrift for Læger · 27.04.2026 · 1-4
DOI: 10.61409/v12251037 ↗Kurz gefasst
Fallbericht in der Zeitschrift Ugeskrift for Læger, online erschienen am 27.04.2026. Verfasst von Sigrid B Gribsholt und 3 weiteren Autor:innen. Beteiligte Einrichtung: Steno Diabetes Center Aarhus, Aarhus Universitetshospital. Hauptthemen laut MEDLINE: Lipomatosis, Multiple Symmetrical, Leptin.
Abstract (Originalsprache)
Multiple symmetric lipomatosis, or Madelung’s disease, is a rare condition with symmetrical fat deposits on the upper body, increasingly associated with genetic mutations. In this case report, we present a patient with an mitofusin 2 mutation causing mitochondrial dysfunction and extremely low leptin. Treatment with metreleptin led to reduced appetite, 17% weight loss, improved triglyceride levels, insulin sensitivity, and reduced liver fat. This is the first published Danish case; metreleptin shows promising results in the treatment of rare leptin-deficient lipodystrophic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Steno Diabetes Center Aarhus, Aarhus Universitetshospital.
- Klinik for Hormon- og Knoglesygdomme, Aarhus Universitetshospital.
- Institut for Klinisk Medicin, Aarhus Universitet.
Zitieren
APA
Gribsholt, S. B., Bruun, J. M., Pedersen, S. B., & Richelsen, B. (2026). Leptin treatment of multiple symmetric lipomatosis due to a mitochondrial defect. Ugeskrift for Læger, 1-4. https://doi.org/10.61409/v12251037
Vancouver
Gribsholt SB, Bruun JM, Pedersen SB, Richelsen B. Leptin treatment of multiple symmetric lipomatosis due to a mitochondrial defect. Ugeskrift for Læger. 2026:1-4. doi:10.61409/v12251037
BibTeX
@article{Gribsholt2026,
author = {Gribsholt, Sigrid B and Bruun, Jens M and Pedersen, Steen B and Richelsen, Bjørn},
title = {Leptin treatment of multiple symmetric lipomatosis due to a mitochondrial defect},
journal = {Ugeskrift for Læger},
year = {2026},
pages = {1--4},
doi = {10.61409/v12251037}
}
EUVIMED